Refeyn, the company behind pioneering mass photometry technology, announces that mass photometry has been recognized by the U.S. Pharmacopeia (USP)—and referenced in the new draft USP general chapter ...

Refeyn, announces the launch of MyMass™ mass photometer (MyMassMP), a compact instrument designed to answer a critical research question: Is the sample good enough for further analysis?

Refeyn, the company behind pioneering mass photometry technology, has been named in The Sunday Times 100 Tech 2026, an annual ranking of the fastest-growing private technology companies in the UK. The ...

As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and analytical strategies must evolve together. In this joint webinar, Minaris ...

A recently-developed technique for measuring the mass of single molecules in solution has the potential to help companies using adeno-associated viruses (AAV) as a vector for gene therapies. That’s ...

A benchtop tool for detecting empty-full viral capsids for gene therapy applications has added the capability to work in commercial-scale manufacturing. That’s according to James Wilkinson, PhD, VP of ...

Biochemical and structural studies of membrane proteins have long been restricted to their isolated soluble domains. This limitation has prevented the study of complexes involving full-length membrane ...